Tag: NYSE:ABT

BioTech

Healthcare Active Runners: Peregrine Pharmaceuticals (NASDAQ:PPHM), Bristol-Myers Squibb (NYSE:BMY), Abbott Laboratories (NYSE:ABT), Teva Pharmaceutical Industries (NYSE:TEVA)

Peregrine Pharmaceuticals (NASDAQ:PPHM) is scheduled to be releasing its Q314 earnings data on Friday, March 7th. Peregrine Pharmaceuticals (NASDAQ:PPHM) stock performance was 47.64% in last session and finished the day at $2.82. Traded volume was 36.76million shares in the last session and the average volume of the stock remained 3.12million shares. The beta of the stock remained 1.40. Peregrine Pharmaceuticals (NASDAQ:PPHM) insider ownership is 16%. … Continue reading Healthcare Active Runners: Peregrine Pharmaceuticals (NASDAQ:PPHM), Bristol-Myers Squibb (NYSE:BMY), Abbott Laboratories (NYSE:ABT), Teva Pharmaceutical Industries (NYSE:TEVA)

Colin Pettis
Finance

Healthcare ACtive Runners: Teva Pharmaceutical Industries (NYSE:TEVA), Exelixis (NASDAQ:EXEL), Novavax (NASDAQ:NVAX), Abbott Laboratories (NYSE:ABT), Celgene (NASDAQ:CELG)

Just a month ago, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) snapped up portfolio company, San Mateo, CA-based Labrys Biologics, for $200 million up front and another $625 million in milestones. That deal came less than two years after Labrys was formed, and venBio partner and co-founder Corey Goodman told Xconomy at the time that venBio had contributed $8.5 million of Labrys’ $31 million Series A round plus an … Continue reading Healthcare ACtive Runners: Teva Pharmaceutical Industries (NYSE:TEVA), Exelixis (NASDAQ:EXEL), Novavax (NASDAQ:NVAX), Abbott Laboratories (NYSE:ABT), Celgene (NASDAQ:CELG)

Jason Knox